Wednesday, April 15, 2015 6:09:04 AM
NEW YORK, NY--(Marketwired - Apr 30, 2014) - Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations announced today that its Idant Laboratories subsidiary has once again been granted accreditation by the American Association of Blood Banks (AABB) for the collection, freezing and storage of one's own blood. Idant Laboratories is a pioneer in blood banking, and was the first laboratory registered to provide long-term self-storage of blood to the public. Idant Laboratories can store individuals' frozen red blood cells for up to ten years. Such frozen blood is then available for future use, such as during a scheduled elective surgery or in an emergency. By storing their own blood for future use, patients may avoid many of the risks commonly associated with blood transfusions, including infections. The accreditation follows an intensive on-site assessment by specially trained AABB auditors who determine whether each facility meets their rigorous technical and administrative proficiency standards.
The President of Daxor, Dr. Joseph Feldschuh, fractured his hip on February 4, 2014 and lost more than one third of his blood. He received a single unit of his own blood which had been frozen four and a half years ago. He had never expected he would have to utilize his own blood. The present guidelines at many hospitals permit patients to lose almost half the blood in their body and have it replaced with salt water unless the patient is symptomatic. Unfortunately sometimes the first symptom is a complete collapse of their circulation, which may lead to a massive stroke, heart attack, or even sudden death.
A recent article in the Wall Street Journal discussed the increasing amounts of people who are storing cord blood which is obtained during the birth of a child. The article noted that the chance of needing to utilize one's own cord blood is approximately 1 in 2,700. In contrast, individuals have a better than 50% chance of requiring a blood transfusion at some point in their lives. Utilization of one's own blood is far safer than use of donor blood for many reasons such as no immuno-suppression and no chance of contracting an undetected infection.
Millions of Americans, such as patients utilizing anti-coagulants, are at a significantly increased risk of bleeding. Unfortunately, only a tiny fraction of these patients take the precaution of storing their own blood in the event of unanticipated bleeding. Pregnant women lose significant amounts of blood during childbirth. The New York State Department of Health has issued a notification about the unacceptable death rate during childbirth from excessive bleeding. The utilization of self-storage of frozen blood can reduce these risks. Daxor Corporation has provided these services since 1987.
http://finance.yahoo.com/news/daxor-corporations-idant-laboratories-subsidiary-123000772.html
Recent DXR News
- Daxor Corporation Acquires Volumex® and Megatope® From Its Existing Supplier Along With Glofil® to Enhance Existing Suite of Diagnostics • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
- Daxor Corporation to Hold Investor Call Discussing Fiscal Year 2023 Financial Results and Corporate Update on March 25, 2024 • GlobeNewswire Inc. • 03/22/2024 12:00:00 PM
- Daxor Corporation Reports Increase in NAV to $7.08 Per Share and 31.8 Percent Increase in Unaudited Revenue of Operating Division for the Year Ended December 31, 2023 • GlobeNewswire Inc. • 03/18/2024 06:18:00 PM
- Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders • GlobeNewswire Inc. • 03/18/2024 06:18:00 PM
- Daxor Announces Sales to Three New Hospitals Furthering Expansion of Its User Base • GlobeNewswire Inc. • 03/11/2024 12:00:00 PM
- Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend] • Edgar (US Regulatory) • 03/08/2024 06:49:31 PM
- Multi-Center Study Presented by Duke at Heart Failure Therapeutics Conference Highlights Daxor’s Unique Clinical Utility for Heart Failure Patients • GlobeNewswire Inc. • 03/08/2024 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 09:18:32 PM
- Form NT-NCSR/A - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report): [Amend] • Edgar (US Regulatory) • 02/29/2024 10:28:32 PM
- Form NT-NCSR - Notice under Exchange Act Rule 12b-25 of inability to timely file Form N-CSR (annual or semi-annual report) • Edgar (US Regulatory) • 02/29/2024 09:15:19 PM
- Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference • GlobeNewswire Inc. • 02/26/2024 01:00:00 PM
- Daxor Corporation Starts 2024 with Ongoing Growth in New Blood Volume Analyzer Acquisitions • GlobeNewswire Inc. • 02/12/2024 01:00:00 PM
- Daxor Corporation Closes Q4 2023 with Growth in New Sales to Hospital Systems and Increased Utilization of its BVA-100® Blood Volume Diagnostic Across the U.S. at Existing Accounts • GlobeNewswire Inc. • 02/07/2024 01:00:00 PM
- Daxor Corporation to Exhibit at the Society of Nuclear Medicine and Molecular Imaging Mid-Winter and American College Nuclear Medicine Annual Meeting • GlobeNewswire Inc. • 01/29/2024 01:00:00 PM
- Daxor Corporation to Exhibit at the Society for Critical Care Medicine 2024 Critical Care Congress • GlobeNewswire Inc. • 01/16/2024 01:00:00 PM
- DAXOR AWARDED ADDITIONAL NEW PATENT FOR SMART BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMES • GlobeNewswire Inc. • 01/09/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2024 01:52:42 PM
- Daxor Corporation Submits Dual 510(k)/CLIA-waiver Application to the FDA for Its Advanced Next-Generation Blood Volume Analyzer • GlobeNewswire Inc. • 01/02/2024 01:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2023 08:48:37 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 02:00:56 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/02/2023 01:58:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 11:03:38 AM
- Form NPORT-P - Monthly Portfolio Investments Report on Form N-PORT (Public) • Edgar (US Regulatory) • 11/24/2023 06:53:43 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM